Sanofi shares fell 1.7% to $75.75 after the company announced it was stopping the Phase 3 MOBILIZE trial of riliprubart, an investigational complement-inhibiting antibody being tested in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not benefited from standard treatments.
The decision followed an interim analysis conducted by an independent data monitoring committee, which determined the MOBILIZE study was unlikely to generate adequate evidence of efficacy to justify continuation. The committee did not identify any safety signals related to riliprubart during this interim review.
Sanofi indicated that terminating the MOBILIZE Phase 3 trial will not result in any material financial cost and that its financial outlook for 2026 is unchanged. Nevertheless, the failure to show likely efficacy in MOBILIZE creates uncertainty around the broader riliprubart development program.
Sanofi said it will reassess other ongoing riliprubart studies in light of the MOBILIZE outcome. That includes the VITALIZE Phase 3 trial, which is evaluating riliprubart in IVIg-treated CIDP patients; continuation of that and other studies will be considered accordingly.
The announcement compounds a run of disappointing clinical results for the company beginning in 2025, increasing pressure on Sanofi to develop or acquire new assets that could help offset revenue risks as Dupixent approaches loss of exclusivity.
The wider market offered little support on the news. U.S. equities were mixed, with the S&P 500 edging lower and the NASDAQ under relatively greater pressure, a cautious risk tone that amplified the adverse reaction to Sanofi's pipeline update.
CIDP is characterized in the announcement as a rare neurological disorder that produces progressive weakness and sensory loss in the arms and legs. The company noted that roughly 30% of patients with CIDP do not respond to standard therapies, a factor that had focused attention on riliprubart as a potential option for this unmet need.
Market reaction pushed the stock to an intraday low of $75.37, a level well below Sanofi's 52-week high of $91.15. The company framed the stop of MOBILIZE as a difficult but necessary decision driven by the interim efficacy assessment.
Context and implications
The halt of a late-stage study is a significant development for Sanofi's clinical pipeline and highlights the uncertainty inherent in developing therapies for rare diseases. While the company is not expecting a meaningful financial impact from the termination and is maintaining its 2026 guidance, the result raises questions about whether riliprubart can deliver the efficacy that had made it one of the more closely watched assets addressing an unmet need in CIDP.
Sanofi will need to weigh the MOBILIZE outcome when deciding the fate of VITALIZE and other trials. Investors are also likely to view this result in the context of the company's broader 2025 trial disappointments and the strategic imperative to replace revenue streams tied to Dupixent ahead of its loss of exclusivity.
Market data referenced
- Share price reaction: down 1.7% to $75.75, session low $75.37
- 52-week high: $91.15
- U.S. market tone: S&P 500 modestly lower, NASDAQ under heavier pressure